DBV Technologies | DBVT - Operating Expenses



DBV Technologies reported $41.11M in Operating Expenses for its fiscal quarter ending in June of 2025.


Operating Expenses Change Date
Acadia Pharmaceuticals USD 232.19M 7.16M Jun/2025
Alnylam Pharmaceuticals USD 789.89M 213.78M Jun/2025
Amarin USD 58.77M 56.06M Mar/2025
BioMarin Pharmaceutical USD 548.52M 27.27M Jun/2025
DBV Technologies USD 41.11M 13.74M Jun/2025
Halozyme Therapeutics USD 123.28M 48K Jun/2025
Incyte USD 904.7M 56.97M Jun/2025
Insmed USD 361.29M 20.33M Jun/2025
Ionis Pharmaceuticals USD 312.21M 34.21M Jun/2025
Neurocrine Biosciences USD 541.9M 7M Jun/2025
PTC Therapeutics USD 213.73M 7.86M Jun/2025
Sarepta Therapeutics USD 495.51M 549.73M Jun/2025
Ultragenyx Pharmaceutical USD 274.38M 7.85M Jun/2025
United Therapeutics USD 521.7M 110.1M Jun/2025